Literature DB >> 11291744

A novel and simple type of liposome carrier for recombinant interleukin-2.

E Kanaoka1, K Takahashi, T Yoshikawa, H Jizomoto, Y Nishihara, K Hirano.   

Abstract

The strong interaction between recombinant interleukin-2 (IL-2) and liposome was characterized and its possible application to drug-delivery control considered. The liposomes were prepared with egg phosphatidylcholine, distearoyl-phosphatidylglycerol (DSPG), dipalmitoyl-phosphatidylcholine, dipalmitoyl-phosphatidylglycerol or distearoyl-phosphatidylcholine (DSPC). Small and hydrophobic liposomes were selected, which were composed of saturated and long-fatty-acid-chain phospholipids. When the composition and the mixture ratio of IL-2 and the liposomewere optimized, morethan 95% ofthe lyophilized IL-2 (Imunace, 350000 JRU) was adsorbed consistently onto the DSPC-DSPG liposome (molar ratio, 10:1; 25 micromol mL(-1); 30 nm in size). Merely mixing IL-2 lyophilized with liposome suspension is convenient pharmaceutically. After intravenous administration to mice, liposomal IL-2 was eliminated half as slowly from the systemic circulation as free IL-2, with more than 13 and 18 times more IL-2 being delivered to the liver and spleen, respectively. After subcutaneous administration of liposomal IL-2 to mice, the mean residence time of IL-2 in the systemic circulation was 8 times that of free IL-2. These results show that IL-2 consistently adsorbs onto the surface of liposomes after optimization of its composition and mixing ratio. Intravenous and subcutaneous administration to mice demonstrates the gradual release of IL-2. Further trials are warranted using these liposomes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11291744     DOI: 10.1211/0022357011775523

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits.

Authors:  Michael-Joseph Gorbet; Akansha Singh; Chenkai Mao; Steven Fiering; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 2.  Delivery of therapeutic proteins.

Authors:  Dipak S Pisal; Matthew P Kosloski; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

Review 3.  The big picture on nanomedicine: the state of investigational and approved nanomedicine products.

Authors:  Michael L Etheridge; Stephen A Campbell; Arthur G Erdman; Christy L Haynes; Susan M Wolf; Jeffrey McCullough
Journal:  Nanomedicine       Date:  2012-06-06       Impact factor: 5.307

4.  A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins.

Authors:  Won Il Choi; Nazila Kamaly; Lorena Riol-Blanco; In-Hyun Lee; Jun Wu; Archana Swami; Cristian Vilos; Basit Yameen; Mikyung Yu; Jinjun Shi; Ira Tabas; Ulrich H von Andrian; Sangyong Jon; Omid C Farokhzad
Journal:  Nano Lett       Date:  2014-10-21       Impact factor: 11.189

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.